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From Angiotensin to Renin to 
Prorenin and from the Adrenal to 
the Kidney to the Placenta and the 
Lungs: An Historical Journey
Alan Poisner
Abstract
In 1966 I carried out a study on the role of calcium on angiotensin’s stimulant 
effects on the adrenal medulla. Since then I have been studying the renin- 
angiotensin system (RAS) for over a half-century in a wide variety of biological 
preparations, while awareness of its complexity has exploded. My journey has 
involved studies on genes, proteins, organelles, cells, tissues, glands, organs and 
whole animals. This chapter reviews what my colleagues and I have learned from 
these different levels of organization and is not meant to be an update on all fea-
tures of the RAS. My studies have included experiments on: perfused cat adrenal 
glands; genetic and second messenger control of catecholamine synthesis and 
secretion from cultured bovine chromaffin cells and from rats in vivo; renin storage 
and release in the rat kidney and secretory granules; properties of isolated renin, 
prorenin and renin-like proteins; hormonal and second messenger control of pro-
renin secretion from human utero-placental tissues; renin/prorenin in a variety of 
tumors; and the effect of RAS drugs in a rodent model of pulmonary fat embolism. 
This most recent study has direct clinical application. I conclude with what I have 
learned about biomedical research and lessons for the future.
Keywords: angiotensin, renin, prorenin, prorenin receptor, renin-angiotensin 
system, adrenal medulla, lungs, kidney, placenta, chromaffin granules, calcium,  
fat embolism
1. Introduction
Awareness of the complexity of the renin-angiotensin system (RAS) has 
increased exponentially since it was initially considered relevant only to hyper-
tension and has led to an explosion of understanding in biochemistry, molecular 
biology, cell physiology, anatomy, pharmacology, and pathophysiology. I have been 
involved in studies at all these levels in a wide variety of experimental models in 
animals and humans for over 50 years. This chapter is a review of what my col-
leagues and I have learned over the course of this half-century. This is not meant 
to be an update on all features of the RAS but rather the advances over the years 
in my personal research journey. It represents almost half of my total research 
publications.
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This has included studies on the effects of angiotensin on the adrenal medulla 
in intact cat adrenal glands and cultured bovine chromaffin cells, renin storage and 
release in the rat kidney and secretory granules, properties of isolated proteins, 
hormonal and second messenger control of prorenin presence and secretion from 
human utero-placental tissues and renin/prorenin in a variety of tumors. These 
studies have implicated the RAS in a rodent model of pulmonary fat embolism syn-
drome (PFE) and showed that drugs acting at different steps in the RAS provided 
protection, suggesting that this approach could be useful in treating/preventing this 
potentially fatal condition. Investigating the RAS in many models in animals and 
humans should increase our understanding of normal and pathological processes 
and thus improve therapy/prevention of a variety of diseases. For the sake simplic-
ity the term renin will be understood to mean total renin (renin + prorenin) unless 
specified otherwise. In extrarenal sites, prorenin may be the only one present and 
it can have some catalytic activity even without processing to the smaller protein 
renin, especially when bound to its membrane receptor.
2. Angiotensin and the adrenal medulla
2.1 Mechanism of short-term effects on the intact adrenal gland
In the early 1960s, evidence was presented that angiotensin II (Ang) could evoke 
the release of aldosterone from the adrenal cortex and catecholamines from the 
adrenal medulla, but the cellular mechanisms had not been completely identified. 
Since my colleagues and I had been mining the role of calcium in adrenal medullary 
secretion in response to acetylcholine [1], we decided to examine peptides in our 
studies and found that extracellular calcium was required for the stimulant effect 
of Ang [2]. Interestingly, one of the earliest demonstrations of the direct effect of 
Ang on adrenomedullary hormone secretion was carried out in 1963 in the labora-
tory of Wilhelm Feldberg at the National Institute for Medical Research in London 
[3] at which time I was working in the same lab on a different project during my 
postdoctoral training. Their study and our later one were carried out on the isolated 
perfused adrenal glands of cats. This is when I gained experience and insight into 
the value of using intact tissues in experimental studies without disruption of their 
cellular connections and revealed the immediate effect of treatment with peptides 
and amines. We could also stimulate the splanchnic nerve in these preparations to 
more closely simulate the natural signaling condition. Further studies on the role 
of calcium in stimulus-secretion coupling revealed its fundamental importance in 
exocytosis in exocrine secretion and neurosecretion [4–6]. This was summarized in 
several review papers [7–9] .
2.2 Mechanisms of long-term effects on adrenal chromaffin cells
The next time that I had occasion to study the effects of Ang was over 20 years 
later when I was working on sabbatical in the laboratory of my former student, Dr. 
J.S. Hong, at the National Institute of Environmental and Health Sciences. His lab 
was interested in the long-term effects of agents on the adrenal medulla (as a surro-
gate for postganglionic sympathetic nerves) and the potential feedback on enzymes 
and peptides. In a series of experiments on isolated chromaffin cells, our group 
found that a stable Ang peptide (S-Ang) increased the secretion and expression 
of catecholamines and met-enkephalin as well as the mRNA expression of several 
catecholamine synthetic genes (tyrosine hydroxylase and phenylethanolamine 
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N-methyltransferase) [10, 11]. The time course of the response to S-Ang showed 
both short-term and long-term effects and revealed the increased expression of 
the oncogene c-fos [12] and its role in nuclear stimulation. These changes were 
mimicked by in vivo stimulation in rats by insulin [12]. These experiments directly 
implicated intracellular calcium as a second messenger leading to nuclear mRNA 
synthesis that required a lag time that followed catecholamine release [11].
2.3 Evidence for endogenous generation of Ang in chromaffin cells
We found evidence that endogenously released Ang from chromaffin cells could 
initiate the secretion of catecholamines and met-enkephalin from bovine chromaf-
fin cells [13, 14]. It is likely that the enzyme responsible for this is renin since renin 
has been found in the adrenal medulla and in chromaffin cells [15]. Prorenin was 
not found in these cells in control animals. These results suggest that there may be 
some autocrine regulation of adrenomedullary secretion mediated by the RAS.
3. Renin and the kidney
3.1 Properties of renin substrate
In the 1970s, we turned our attention to studies on renin and the analytical 
method of the day was to measure the generation of angiotensin I using a protein 
or polypeptide substrate. The literature indicated that renin activity from various 
sources was not inhibited by the usual SH-targeting agents but was potentiated in 
some cases by the SH-protecting agent dithiothreitol (DTT). Since we intended to 
find a useful substrate, we first studied the interaction of DTT with renin and/or 
several renin substrates (angiotensinogen). The commercially substrate available at 
the time was hog renin substrate but we also prepared a semi-purified bovine sub-
strate. We found that the potentiating effect of DTT was exerted on the substrate 
(bovine or porcine) and not on renin [16].
3.2 Subcellular storage of renin
Using our sensitive enzymatic assay and radioimmunoassay (RIA) for angio-
tensin I, we were able to initiate a number of studies on the storage of renin in the 
kidney using knowledge gained from our previous studies on secretory granules 
from the adrenal medulla [17] and the posterior pituitary [18]. The goal was to 
understand secretory mechanism for renin utilizing the secretory granules from the 
juxtaglomerular cells of the renal cortex. There had been a few studies on storage 
of renin but no systematic studies to understand their physical properties and the 
effect of isolation techniques. In our initial study we took into consideration what 
we had learned about the influence of temperature and pH on other secretory 
granules and found that crude rat kidney renin secretory granules were more stable 
when isolated at room temperature (22–25°) than at 0° and were most stable at 
pH 6.0 [19]. They were also somewhat stabilized by MgATP unlike adrenal chro-
maffin granules [20]. Later studies with more purified granules confirmed that the 
granules were more stable at room temperature but were labile if transferred from 
hyperosmotic density gradient media back to physiological tonicity [21]. When 
these purified granules were incubated at 37° instead of room temperature they 
again showed lability when they were subsequently incubated at 0° [22]. In order 
to avoid the problems with isolation in hypertonic media, we employed density 
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gradients with lower osmotic properties and at room temperature. These granules 
were stable as long as there were not transferred to 0° media and kept not far from 
pH 6.0 [23]. Granules prepared in isotonic density gradient media showed two 
peaks with short term centrifugation that was resolved with longer term prepara-
tion, suggesting that renin granules are of two sizes with the same density [23].
3.3 Renin-like activity in the rat in vivo
When we began to study renal granules, we became aware of a study of another 
angiotensin I-generating enzyme that had a lower pH optimum and preferred 
the tetradecapeptide substrate rather than the protein substrate. They called it 
pseudorenin [24]. It was found in rat plasma and a wide variety of tissues and 
in much higher concentrations in the salivary gland and the spleen than in the 
kidney. Since we could not find any physiological studies of pseudorenin in intact 
animals, we examined the changes in plasma pseudorenin and renin in rats after 
nephrectomy and in response to converting enzyme inhibition and beta-adrenergic 
receptor blockade. We found that, unlike renin, plasma pseudorenin increased after 
nephrectomy and treatment with propranolol but did change after angiotensin 
converting enzyme treatment [25] . Later we examined bovine spleen and provided 
evidence that pseudorenin is cathepsin D [26] .
4. Renin in human tumors
4.1 Enzymatic analysis
Although there had been several reports of increased renin activity in serum or 
tissues of patients with renal tumors using bioassays for analysis [27, 28], none had 
followed the clinical course and biochemical evaluation of the patients and utilized 
agents interfering with angiotensin to modulate the course of the disease. We 
reported on a patient with bilateral Wilms tumor (nephroblastoma) who exhibited 
congestive heart failure, hypertension and elevated serum renin using a more 
contemporary radioimmunoassay and an international standard [29]. We found the 
patient’s clinical course and tumor size in response to surgery and chemotherapy 
were paralleled by serum renin concentrations (PRC) and his hypertension was 
ameliorated by saralasin, a peptide angiotensin receptor antagonist (this was before 
non-peptide ARBs were available). We were able to assay samples with exceed-
ingly high renin concentrations that would not be possible with simple plasma 
renin activity (PRA) assays since these high dilutions would reduce the available 
endogenous substrate to suboptimal levels. For our assays, we used substrate from 
nephrectomized sheep that was known to be a better substrate for human renin. 
Plasma renin concentration was over 4600 μU/ml before therapy (normal 30–90 in 
our lab) and fell to 69 after chemotherapy and surgery. A few months later the 
tumor size increased and so did the renin concentration [29] A partially resected 
tumor mass was found to contain renin by immunohistochemical and biochemical 
analysis (1245 μU/g).
4.2 Immunohistochemical analysis
To utilize a non-enzymatic method to localize renin, we utilized a specific 
antirenin antiserum and examined several non-renal tumors. In preliminary 
studies we found renin and prorenin in complete and incomplete hydatidiform 
moles [30, 31]. By 1990, prorenin was a widely accepted name for what had one 
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time been called “inactive renin” and we reported on its presence in cyst fluid and 
ascites in patients with ovarian tumors [32].
5. Renin/prorenin in human amniotic fluid and amnion
5.1 Purification and properties
When considering the possibility of alternative forms of renin, we noted the 
report of high concentrations of renin in human amniotic fluid [33] and sought 
to purify the enzyme from this source. We noted that the original description of 
renin in amniotic fluid included a step of acidification and that it was subsequently 
found that this caused an activation of “inactive renin”. We compared chromato-
graphic and kinetic properties of endogenous renin, acid- and pepsin-activated 
renin using bovine and hog substrate and found differences between acid- and 
pepsin-activated renin [34]. Further purification of the inactive renin allowed 
separation from the pseudorenin mentioned above that was similarly inhibited 
by pepstatin [35, 36]. We developed an assay utilizing a single tube for renin-
generated angiotensin I and the subsequent radioimmunoassay which greatly 
facilitated these studies [37]. We also showed that both prorenin and active renin 
were inactivated by ethyl diazoacetylglycinate, a compound known to inactivate 
aspartyl proteases but not pepsinogen [38].
5.2 Localization, synthesis and release from amnion
We initially demonstrated the presence of the renin and prorenin with both acid 
and trypsin activation using nephrectomized sheep plasma substrate. This showed, 
like amniotic fluid, that the bulk of the potential angiotensin-generating activity was 
in the inactive (IR)-prorenin form (about 70% in these samples) [39]. Our immuno-
fluorescence study, using antiserum to human kidney renin, showed that the positive 
cells were the amniotic epithelial cells and not contaminating chorionic cells [39]. We 
noted at the time that early initial attempts to show synthesis by cultured amniotic cells 
were negative [40]. Those studies included bioassays of samples that had initially been 
treated at pH 3.0 so some prorenin would have been activated and recorded as renin 
[40]. In our study where we did not expose samples to low pH and used trypsin activa-
tion to assay IR, we found no IR or R in medium from cultured amniotic cells although 
similarly cultured chorionic cells produced enormous quantities of IR/prorenin that 
sometimes required a dilution of 1000× to bring the samples into the assay range [41].
In another model, to assess the potential synthesis of IR from the amnion, 
we superfused separately the amnion and the chorion from a clamped fetal 
membrane in a Ussing chamber device. We found that there was a dramatic and 
increasing release from the chorion side but a low and decreasing amount from 
the amnion side [41]. Furthermore, when a high concentration of IR previously 
released on the chorion side, was superfused on the chorion side, there was no 
increase on the amnion side, thus excluding leakage or transport [41]. Since there 
are many sources of prorenin in the human uteroplacental complex at term preg-
nancy [42], there could be more than one source of its presence in amniotic fluid. 
That could include uptake from fetal urine since prorenin has been found in urine 
[43] and an uptake system in amnion has been reported [44]. The latter group 
used amnion explants and found very low levels of renin mRNA and extremely 
low levels of prorenin protein release but considered that the decidua could be the 
source of amniotic prorenin. There was no evidence of de novo synthesis in our 
experiments using undigested amnion [41].
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6.  Prorenin production and release from human chorion and chorionic 
trophoblasts
6.1 Purification and properties
After determining that the amnion was not a likely source of prorenin in the 
amniotic fluid, we turned our attention to the other major fetal membrane, the 
chorion, and more specifically the chorion leave (free chorion). In our initial report 
[45], we noted the early work that suggested that Hofbauer cells (fetal macro-
phages) and not trophoblasts or fibroblasts were the renin-containing cells, using 
the Bowie stain that showed renin in the kidney We used an immunofluorescence 
technique and employed an antiserum to a highly purified renin preparation from 
human kidney that we subsequently realized recognized both renin and prorenin. 
We found that the renin immunoreactivity in the chorion was strictly localized to 
the cytotrophoblast layer [45]. Subsequent biochemical studies showed that the 
“inactive renin” from chorion and culture medium from chorionic cells is definitely 
prorenin [46]. In addition, we found that this same cell layer was positive for hCG 
[47] and there was a relatively constant ratio of renin/hCG in purified chorionic 
cells: 5.14 μU renin/mIU hCG. Here and elsewhere the terms renin and prorenin and 
IR are used interchangeably except where noted since all or almost all the renin is 
present as prorenin.
6.2 Release of prorenin and hormones from intact membranes and isolated cells
We used our superfused membrane, preparation to show that both prorenin and 
hCG were released at a constant or increasing rate even after 80 minutes [47]. An 
interesting finding from our studies on the superfused chorion was the short term 
release of prorenin by angiotensin II [48]. We also found that angiotensin induced 
the release of LHRH (GnRH)-like activity from this preparation [49]. In parallel 
experiments we demonstrated specific binding of angiotensin II to these cells [49].
Since the purified chorionic cells could be grown in tissue cultures for many 
days, we were able to examine factors that might modify synthesis and release 
in the short or long term. We could even grow these cells for periods up to 
3 months without them losing their capacity to synthesize and release prorenin 
[41, 48]. When we examined these cells for the steroid hormone progesterone 
that had been reported to be present in the chorion, we found they indeed did 
contain progesterone and its synthesis and release could be promoted by various 
precursor steroids. (pregnenolone and 25HC) [50]. The amount of progesterone 
released greatly exceed the amount initially found in these cells and the syn-
thesis and secretion were both promoted by agents acting to raise cyclic AMP 
(cAMP) [50]. These included dibutyryl cAMP, methyl isobutyl-xanthine (MIX), 
forskolin and cholera toxin. Prorenin secretion by these cultured cells was also 
promoted by MIX and cholera toxin and especially by cholera toxin in the pres-
ence of phorbol myristate acetate (PMA), a protein kinase C agonist. In some 
cases, the concentration after 72 hours of incubation with these agents reached 
700,000 IU/ml. This was not due to an increase in cell numbers since these were 
confluent monolayers [48]. The dramatic potential for term chorion to synthesis 
and release prorenin clearly differentiates the secretory process from the renal 
secretion of renin where it is stored primarily in dense secretory granules and 
is presumably released by conventional regulated exocytosis. We have found 
prorenin in the chorion to be mostly in the cytoplasmic fraction of the tissue and 
not in particulate fractions [49].
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7. Prorenin production and release from decidua
7.1 Primary and second messengers
After a report in 1989 that decidual cells have the capacity to synthesize and 
release active and total renin from decidua [51], we turned our attention to the 
maternal portion of the feto-placental unit. The first potential hormonal/primary 
messenger that we examined was relaxin [52] . This hormonal messenger was 
known to be present in chorion and decidua [53]. We found that renin released 
from cultured purified decidual cells was 95% prorenin when we did not expose 
the samples to acidification as was done in the earlier report [51] and that relaxin 
caused a dose-dependent increase in release that was paralleled by an increase in 
tissue prorenin and was inhibited by cycloheximide [52]. This was consistent with 
new protein synthesis. We cited the views at the time on relaxin’s potential effects 
on uterine ripening and decidual prolactin release. This was one of many pieces of 
our studies on the utero-placental complex that pointed to paracrine or autocrine 
effects in supporting local autonomy.
The next potential positive regulator of prorenin release that we examined was 
endothelin since it was known to be present in the placenta and had been found to 
modify renin release from the kidney. We found that several endothelin peptides 
caused a dose-dependent release of prorenin that was associated with an increase 
in renin mRNA [54]. The release was greater than the control content and was not 
associated with the release of cellular prolactin. This was another clear example 
of prorenin secretion by the protein synthesis-dependent constitutive secretion. 
Further studies on the effect of endothelin (ET-1) on prorenin release showed a 
clear difference from the control of prolactin (PRL) release The calcium ionophore 
A-23187 stimulated basal prorenin release and potentiated ET-1 stimulated release 
while having no effect on PRL release; and the calcium channel blocker nifedipine 
blocked the effect of ET-1 on prorenin but had no effect on PRL [55]. The protein 
kinase C agonist PMA stimulated basal and potentiated ET-1 induced prorenin 
release but inhibited basal PRL release and potentiated the inhibitory effect of 
ET-1 [55]. Finally, the PKC inhibitor staurosporine increased basal PRL release 
and reversed the inhibitory effect of ET-1 on PRL release. These results indicate 
that prorenin and PRL release from decidua are affected in different directions by 
protein kinase C and that prorenin release is dependent on extracellular calcium but 
PRL release is not [55]. In addition to protein kinase C and calcium, we also studied 
the influence of cyclic AMP (cAMP). We found that agents which elevated cAMP 
in decidual cells also stimulate Pro release. These included forskolin, cholera toxin 
(CT) and dibutyryl-cAMP [56]. Ninety-eight percent of the renin was in the form 
of Pro. PMA potentiated the effects of CT and dibutyryl cAMP. These studies had 
therefore implicated cAMP as well as protein kinase C as second messengers in Pro 
release from decidua.
7.2 Cytokines and prorenin secretion
After a report that lipopolysaccharide (LPS) and tumor necrosis factor-α 
(TNF) stimulated prostaglandin production by decidua [57], we examined the 
effects of these agents on prorenin release from our semi-purified decidual cells. 
We found that LPS inhibited the synthesis and release of both Pro and PRL from 
the decidual cells in a time and dose-dependent manner [58]. We noted at the time 
that the inhibitory effect of LPS might be mediated by the release of cytokines 
from macrophages and then a paracrine effect on stromal cells could ensue. We 
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also indicated that it could also be due to a direct effect on the stromal cells. We fol-
lowed up this study by an examination of the effects of two other cytokines, TNF 
and interleukin-1β (IL-1β). We reported that these cytokines inhibited synthesis 
and release of renin from cultured decidual cells in a dose-dependent manner 
[59] and noted that the cells that were initially plated were composed of 22% 
macrophages (CD-68-staining) and 78% PRL positive (the other major cell type 
in decidual cells). We therefore concluded that the effects of these two cytokines 
could have been mediated by their known actions on macrophages. There was 
no inhibition of DNA synthesis or cell number. It was of interest that the effects 
of these cytokines was opposite to those on the rat renal tissues where there was 
an increase in renin release which occurred in minutes [60] unlike the decidual 
release that took days [59]. The third cytokine that we examined was interferon-ϒ 
(IFNϒ) which was known to have receptors on placental cells. We found that 
IFNϒ inhibited Pro release and its mRNA expression in decidual cells. When we 
employed an additional step of purification using immunomagnetic beads to 
separate the macrophages, we found that renin release from both populations of 
cells was inhibited by IFNϒ and TNF and the combination of these two cytokines 
was even more effective in producing inhibition of release. Since IFNϒ mRNA was 
found only in the macrophage population, while the IFNϒ receptor was found on 
both, it suggested that the effect of locally produced IFNϒ on renin release from 
macrophages could result from both autocrine and paracrine mechanisms while 
effects on stromal cells would be paracrine in nature [59].
7.3 Release of prorenin from macrophages and monocytes
Since we knew that macrophages represented a significant portion of decidual 
cells at term pregnancy and represented about 22% of our decidual cell preparation, 
we decided to examine directly whether these cells could also could be a source of 
prorenin. We utilized a method employing immunomagnetic beads after coating 
the macrophages with HLA-DR antibody to separate the macrophages from stromal 
cells. This increased the portion of HLA-DR (+) cells from 22 to 93%. The purified 
cells no longer showed mRNA for prolactin which was abundantly expressed in the 
non-macrophage population [61]. These cells stained for renin with a specific anti-
body, expressed renin mRNA and released prorenin into culture medium during 
3 days of culture. They did not release prolactin. Importantly, the non-macrophage 
cells also stained positively for renin and released the same amount of renin per 
ug DNA per cell as the HLA-DR (+) cells. They also did not stain for a cytokine 
receptor that was present in the macrophage fraction [61]. These results indicated 
that both types of decidual sells had the capacity to synthesize and release prorenin 
and strengthened the case for possible autocrine/paracrine signaling. In addition, 
we collected some peripheral blood monocytes and demonstrated that they also 
showed mRNA for renin and speculated on some potential functions of the RAS 
within the uteroplacental complex [61].
7.4 Regulation of renin expression and secretion in differentiated monocytic cells
To study the expression and regulation of renin in a pure cell line, we employed 
the well-studied U-937 cells which can be differentiated into a terminal macro-
phage/monocyte phenotype using phorbol dibutyrate (PDBU). We found that the 
treatment did cause a morphological change that was identical to those reported in 
the literature [62, 63] . The differentiated cells expressed renin mRNA and released 
prorenin into culture media [64]. We first looked at the potential regulation by 
cAMP, which we had found to be important in prorenin release from decidual and 
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placental cells [56, 65] and others had found important in renal juxtaglomerular 
cells [66]. Renin mRNA and prorenin release were increased by dibutyryl-cAMP, 
and forskolin. In addition, terbutaline, a β2-adrenergic agonist known to increase 
c-AMP, also increased expression and release of prorenin [64]. The stimulation by 
terbutaline was potentiated by a type IV c-AMP-phosphodiesterase (PDE) inhibi-
tor. It was known that these cells possess β2-adrenergic receptors and the type IV 
PDE. The stimulatory effect of terbutaline on renin secretion was inhibited by an 
angiotensin receptor agonist and also by TNF and LPS+ IFNϒ [64]. Taken together 
with our studies on isolated decidual macrophages [61], these results reinforced 
the potential importance of some components of the RAS in the function of 
macrophages and other bone marrow-derived cells. They also highlight the possible 
positive and negative autocrine actions of local mediators.
8. Studies on villous placenta
8.1 Gestational differences in the RAS in placentas
The villous placenta at term has very low concentrations of renin with higher 
concentrations in decidua and chorion [67, 68]. We hypothesized that the renin 
concentration might be influenced by gestational age as influenced by alterations in 
hormonal milieu and found that this was indeed the case [69]. We found that there 
were dramatically high levels of prorenin and active renin in first-trimester preg-
nancies: prorenin was 1130 μU/mg protein in the first trimester vs. 5.9 at term; the 
corresponding values for active renin were 330 vs. 0.15. As might be expected, the 
values for hCG in the first trimester were also greater than at term (2396 vs. 38.6 
ng/mg protein). However the levels of hCG and prolactin in decidua did not change 
much during gestation and there was no detectable prolactin at any stage in placenta 
[69]. Placental prorenin correlated with chorionic gonadotropin but not prolactin in 
both groups. and could reflect similar cellular origins.
8.2 Experimental preparations to study the RAS in human placenta in vitro
An early preparation that we used was a superfused placental mince that allowed 
investigations of mostly intact cells with normal cellular contacts over a period of 
many hours. With this preparation we showed that there was a dramatic increase in 
prorenin release beginning after 12 hours, reaching levels of 16 μU/ml at 26 hours 
from a basal level about 0.5 or less [70, 71]. This spontaneous increase was blocked 
by cycloheximide and actinomycin D, supporting the conclusion that it required 
new mRNA and protein synthesis, like our results on decidua and chorion. We also 
showed that the spontaneous release could be amplified by treatment with relaxin 
[72]. Further evidence of the increase in synthesis of prorenin was found when we 
measured the tissue content of superfused placental minces after superfusion for 
24 hours with or without the adenyl-cyclase stimulator forskolin. This model was 
useful for rapid kinetic measurements, but the disadvantage was interruption of 
much cellular connections.
Another model that we used was the dually perfused human cotyledon which 
allowed nutrients and drugs to reach cells through vascular channels and permitted 
assessment of vascular reactivity. It was known that AI and AII produced dose-
dependent pressor responses which were blocked by the angiotensin antagonist 
saralasin and the response to AI was blocked by captopril [73]. We showed in this 
preparation that there was no renin released into the fetal circulation but there 
was consistent release into the maternal circuit [74]. It was all prorenin. This 
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preparation suggested that renin in fetal circulation in vivo was not coming directly 
from the maternal vasculature. The advantage of this model was the greater integ-
rity of the in vitro system, but it was restricted by logistical considerations to the 
number of different preparations that could be set up at one time.
The most useful model that we employed retained much cellular connections 
and could be used over longer periods of time. That was based on an early model 
of placental explants, sometimes called organ culture [75]. We found the optimal 
conditions by putting the explants on top of wire-mesh platforms and keeping 
the fluid level at the surface of the tissue. With this model we examined potential 
primary and secondary signals in regulation of the placental RAS.
8.3 Prorenin secretion: primary messengers and modulators
It was known in humans that renal renin secretion was stimulated by catechol-
amines and selectively by β-1 adrenergic agonists [76] and that the villous placenta had 
both β-1 and β-2 adrenergic receptors [77]. When we studied the effects of epinephrine 
and beta-adrenergic agonists on placental renin secretion from placental explants, we 
found that both β-1 and β-2 adrenergic agonists elicited renin secretion, associated with 
an increase in synthesis [78]. Again, this was about 95% trypsin activatable and pre-
sumably prorenin. This is consistent with the view that extrarenal renin in the human 
reproductive track is almost exclusively prorenin [54, 79] . We discussed the likelihood 
that beta-agonist-induced renin secretion would be regulated by activators produced by 
the fetus [78]. At the same time, we found that hCG secretion was selectively stimulated 
by the β-2 adrenergic agonist terbutaline and that its stimulant action was blocked by a 
selective antagonist. We showed that the stimulant effects of beta-adrenergic agonists 
on both renin and hCG secretion were potentiated by selective inhibitors of phospho-
diesterase types III and IV [78]. The differences in agonist selectivity between renin 
and hCG secretion was consistent with findings on their respective localization in term 
placenta, with renin in cytotrophoblasts and hCG in syncytiotrophoblasts [80].
The likelihood that renin and hCG are released in close proximity to one another 
suggests that there might be some paracrine regulation involved. With this model 
system we provided evidence that hCG stimulates renin secretion and tissue 
levels [81]. Furthermore, the stimulation was potentiated by phosphodiesterase 
inhibitors, just like renin secretion, and was accompanied by an increase in media 
cAMP. The effect of hCG was markedly attenuated by the protein kinase A inhibitor 
H-89. These results suggested that placental renin secretion may be regulated in part 
by hCG and mediated by cAMP transduction mechanisms [81]. Further support for 
the influence of cAMP on renin secretion is presented in Section 8.4.
A possible negative regulator on renin release, based on what has been found in 
studies on cultured juxtaglomerular cells (JG), is angiotensin II, where a purported 
negative feedback loop reveals an inhibitory action [82]. We found that a stable 
analog of angiotensin II inhibited the spontaneous release of renin from placental 
explants during the 72 hour incubation [71, 83]. This paralleled a study where 
transfected JG cells released prorenin and not renin [82].
Other negative regulators of placental renin secretion that we identified 
included LPS and the glucocorticoid dexamethasone. They both inhibited sponta-
neous and stimulated renin release [71]. These agents act at many different sites, 
including macrophages, so their influence on renin secretion is complicated.
8.4 Prorenin secretion: second messengers and nuclear signals
We had already identified cAMP as a second messenger for chorion and decid-
ual renin release and we examined if similar mechanisms existed in placental 
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prorenin secretion. Evidence for cAMP mediation was supported by our finding 
that renin release from explants was stimulated by several orders of magnitude 
by forskolin and by cholera toxin (CTX) [83]. The effects were potentiated by a 
cAMP phosphodiesterase inhibitor. The enhanced release of renin was accom-
panied by an increase in hCG found in the media. It is important to note that 
prolactin was not detected in the media, thus excluding decidual contamination. 
This was also supported by the fact that the phosphodiesterase inhibitor did not 
cause an increase in renin release from similarly-treated decidual explants [84]. 
Not only did the tissue levels of renin increase indicating new synthesis, but there 
was a decrease in LDH leakage demonstrating cellular integrity [83]. An interest-
ing finding was that an angiotensin II agonist inhibited both the spontaneous and 
the CTX-enhanced release of renin. This effect was blocked by an angiotensin 
receptor antagonist. Further evidence on the role of cAMP came from our studies 
on cAMP-dependent protein kinase (cAPK) [85]. We found that the dobutamine-
stimulated secretion of renin and cAMP was accompanied by an increase in tissue 
cAPK. We used substituted analogues of cAMP, selective for binding sites on 
cAPK, and found that site B analogues which bound to catalytic or regulatory 
sites were stimulants of renin secretion but that site A analogs were not [85]. 
Strengthening the case for the role of cAPK in dobutamine-induced renin secre-
tion, we found that the specific cAPK inhibitor H-89 blocked secretion and an 
activator SP-cAMPS stimulated secretion [85]. We then used molecular biology 
techniques to assess the role of mRNA synthesis in the stimulation of renin secre-
tion, using the β-1 agonist dobutamine and the β-2 adrenergic agonist terbutaline. 
These agents both increased renin mRNA in a dose-dependent manner which 
paralleled their effects on renin secretion and tissue levels [86]. The effects on 
renin secretion and tissue levels were blocked by cycloheximide (a translational 
inhibitor in protein synthesis) and actinomycin D (a transcriptional inhibitor 
which acts directly on DNA). Actinomycin D blocked the increase in renin mRNA 
but cycloheximide did not, thus showing the specificity of these agents and the 
importance of gene regulation in adrenergic stimulation of placental prorenin 
secretion [86].
Other second messengers that have been studied in a wide variety of tis-
sues including the placenta include eicosanoids, protein kinase C and calcium. 
Prostaglandins have been known to influence renal secretion of renin and are 
actively secreted by utero-placental tissues. We reported that meclofenamate, a 
relatively selective inhibitor of cyclooxygenase, inhibited the release of renin from 
placental cells and (unpublished studies) that it also inhibited the ET-1 induced 
renin release from decidua [71]. As with the decidua, the protein kinase C agonist 
PMA increased renin release from placental explants and the enzyme inhibitor 
staurosporine was inhibitory [71]. The influence of calcium was contrary to many, 
but not all, studies on the kidney where calcium is considered an inhibitory messen-
ger on renin secretion. Extracellular calcium caused a dose-dependent increase in 
short-term renin release between 1.0 and 3.6 mM in contrast to the kidney. It should 
be noted that there are some studies on renal tissues in special situations where cal-
cium is a positive regulator [87–89] and other studies on extra-renal renin secretion 
where calcium also has a positive influence on renin secretion [90, 91]. Similarly, 
angiotensin was shown to have inhibitory effects on the synthesis and release of 
renin from placental explants but was stimulatory during short term exposure of 
superfused chorion [48].
These studies on different anatomical portions of the utero-placental complex 
suggest that local conditions and times of gestation can modulate the regulation of 
the RAS and that studies on single cells may be missing the complex interactions 
that exist in vivo.
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9. Role of the RAS in pulmonary fat embolism
9.1 Fat embolism model in rats
After 40 years in academia and an enormous expansion of information in the 
RAS field, I retired. It was short lived because I still wanted to see new develop-
ments and help in obtaining information. That is why I was eager to join (and 
help revitalize) a project on fat embolism that had been dormant for 40 years. Dr. 
Federico Adler, a retired orthopedic surgeon, asked for my help in restarting a study 
of fat embolism in rats that he had worked on in the 1960s. My focus was gaining 
evidence on the potential role of the RAS in fat embolism syndrome, a sometime 
fatal consequence of long bone fracture (and some other conditions). This brought 
me back to in vivo studies with its advantages and disadvantages. We initially did 
time- and dose-related studies with intravenous dosing of the triglyceride triolein 
and used histochemical methods to evaluate pulmonary pathology. We found that 
there was an early phase beginning very early and peaking at 48 hours [92] with 
inflammatory, fibrotic and vasoconstrictive effects.
9.2 Effect of RAS drugs on pulmonary fat embolism
Since there were reports that some RAS drugs had beneficial effects in other 
types of pulmonary injury, we examined the effects of the angiotensin converting 
enzyme inhibitor (ACEI) captopril and the type 1 antagonist (AT1) losartan when 
given 1 hour after the triolein. Both agents provided significant protection against 
the histopathological effects when viewed at 48 hours [93] and provided strong 
evidence that the acute effects of fat embolism involved the production of angioten-
sin II and actions on the AT1 receptor. In a later study we found that the pulmonary 
injury was also ameliorated by the renin inhibitor aliskiren [94].
We subsequently determined that the initial acute phase after fat embolism 
was followed by a slowly developing smaller inflammatory response and this was 
associated with an increase in the presence of angiotensin peptides [95]. Since 
there were still some fat particles present at this later time period, we suggested 
that one mechanism could be the continued activation of macrophages that were 
engulfing the fat and signaling mast cells (and perhaps other cells) to release 
renin and then local angiotensin release. Some support for this view came from 
two further studies. In one, we gave the AT1 blocker losartan 6 weeks after the 
triolein injection and examined the rats 4 weeks later. In this experiment the 
protective effect of losartan was still demonstrated at this late stage, supporting 
the view of continued activation of the RAS [96]. In another study we found that 
24 and 48 hours after triolein there was an increase in renin staining in lungs 
that diminished but was still present at 3 and 6 weeks [97]. The renin staining 
increased again at this late stage when the rats were treated with lipopolysac-
charide (LPS) [97] which was known to interact with the RAS [98]. Since we had 
suggested that some of this renin could be in mast cells, we examined the presence 
of mast cells in triolein-treated rats and the influence of losartan. We found that 
10 weeks after triolein there was an increase of mast cells and this was attenuated 
by losartan [99]. Addition of LPS at 6 weeks caused slightly more mast cells and 
this was also blocked by losartan. We also considered that macrophages could be a 
source of renin.
In several of our papers, we have suggested that the RAS drugs could be useful 
in the treatment or prevention of fat embolism syndrome and there are some other 
findings of potential clinical interest. The lungs from a pregnant patient who had 
succumbed to a pulmonary fat embolism were examined at our affiliated hospital 
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and showed the same kind of histopathological changes that we had observed 
on our rat experiments [100]. Another point of possible clinical interest was our 
finding that 6 weeks after fat embolism when the animals appeared normal and 
had grown as well as the saline-treated controls, they were especially sensitive to a 
“second hit” with LPS [101]. The potential clinical relevance of these findings is that 
patients who have severe respiratory distress more than would be expected from 
their presenting diagnosis could be suffering from a “second hit” a long time after 
a forgotten trauma which has left a smoldering low-grade inflammatory process 
continuing in the lung. A recent review of our studies on fat embolism syndrome 
has been published online [102] that implicates the RAS as a key component of this 
condition.
10. Role of the RAS in homeostasis and lessons for the future
10.1 Historical developments as seen through my research journey
The latest part of my journey related to the RAS (which is still ongoing) comes 
53 years after my first paper mentioning angiotensin [2] and 59 years after my first 
scientific paper as a medical student [103] . Although I have enjoyed working in 
many areas of biomedical research, it has been very gratifying to see this major part 
of my career get closer to the long-range goal of improving health care for people 
in need. An ironic and maybe not surprising development is that my early and 
long-standing studies on chromaffin granules and their ATPase [17, 20, 104–107] 
have come full circle with the finding that the granules contain renin and prorenin 
[15] and their membranes contain the prorenin receptor [108, 109]; and it is now 
known, but not in the 1960s, that there is a receptor for renin/prorenin (P)RR 
that can act on second messengers independent of the RAS [110, 111] It was also 
not appreciated that there was an opposing arm of the RAS that could antagonize 
many of the deleterious effects of the angiotensin-ACE-AT1 receptor axis. and it is 
ubiquitous in distribution outside and inside the cell [112–115]. My studies and the 
current literature suggest that it will be difficult to find any extra-renal system that 
does not have some components of an endogenous RAS.
10.2 Lessons that I have learned about biomedical research
I will conclude with my views on ways of approaching biomedical research based 
on my experience and lessons that I have learned.
10.2.1 Pharmacological lessons
Many of these lessons were not appreciated when I was a medical student.
a. Low doses of drugs may have opposite effects of higher doses, the hormetic 
effect. Sometimes this is because receptors of different sensitivity are activated 
as the dose is increased. Other times this may be due to non-receptor mediated 
effects, such as enzyme inhibition. An example in the RAS is the activation of 
AT2 receptors by angiotensin II opposing the actions on AT1 receptors and the 
activation of Ang (1–7) receptors as angiotensin II is converted. This is further 
discussed below under moonlighting (10.2.d.).
b. Species differences: It has long been clear that other species may have differ-
ences in metabolism, pharmacokinetics, morphology and a host of features 
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that make direct extrapolation to humans problematic. Also, mice and rats are 
not equivalent when compared to human biology.
c. Short term vs. long term experiments: Many experiments have shown biphasic 
response to drugs with opposite effects seen depending on when the observa-
tions were made. This is an argument for examining time-response curves 
in addition to dose-response curves. This has led in the past to some studies 
missing a response by looking at a single time-point.
d. Response of young animals (organs) may not be the same as that of older ones. 
This has been obvious for a long time since the changes during maturation in 
animal biology has long been appreciated. A striking change during develop-
ment in a single organ has been found in the human placenta as we have noted 
in our studies on the RAS. Of course, the placenta is a unique organ and has 
features of many other organ systems, including the liver, kidney and endo-
crine and nervous systems among others.
10.2.2 Biochemical lessons
Another lesson that was not appreciated is that of moonlighting. This is the 
area pioneered by the ground-breaking research of Constance Jeffery from 1999 
[116] and still expanding in 2018 [117]. It appears that prorenin and the prorenin 
receptor are archetypes of multi-functional proteins. Prorenin (a) serves as the 
zymogen precursor of renin that follows cleavage of the prosegment; (b) becomes 
a catalytically active enzyme without cleavage when bound to its receptor, (c) 
activates a surface membrane receptor coupled to the generation of intracellular 
kinases, and (d) likely serves in several capacities intracellularly [118]. This 
complexity was not imagined at the time we were calling this ‘inactive renin’. 
The prorenin receptor ((P)RR) also has multiple functions, some not related to 
angiotensin peptides [119].
10.2.3 Experimental lessons from genes to molecules to intact humans
I have carried out experiments using extreme reductionist approaches, such 
as studies on isolated proteins and on gene expression. Some of our studies 
were on isolated organelles and on isolated cells. These types of experiments 
removed many cells from their natural environment and from potential neu-
ronal, paracrine, or endocrine modulation. The next step up in complexity 
were studies on isolated perfused glands or tissue slices where there was some 
contact between different cells as in the intact animal but still not complete 
signaling from the entire organism. Finally, I have studied the effects of drugs 
on whole animals in vivo, including humans. The result of this wide range 
of studies has provided me with the following perspective. No one approach 
will give us a complete picture although bringing us closer to a true view of 
what is going on in health and disease. Our reductionist approach strives to 
reduce as many variables as possible and each provides some useful informa-
tion. However, many interactions at higher levels of complexity may be lost or 
overlooked. Only experiments on normal humans could come close to a real 
world understanding but that is beyond ethical consideration. In addition to 
the reservations listed above, our studies do not take into consideration the 
epigenetic, environmental and social factors that influence how we interact 
with internal and external stimuli. Some of this newer point of view includes 
the field of hormesis [120].
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Finally, I have been fortunate to have chosen to study the RAS for much of my 
research career since this system seems to be ubiquitous throughout biology and 
has only in the past five decades begun to reveal the many ways we depend upon its 
proper regulation to maintain our health and suffer when it is out of control.
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